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Abstract
Random mutations were generated in the G-protein-coupled receptor (Ste2p) for the tridecapeptide pheromone (K-factor)
of Saccharomyces cerevisiae. These mutants were screened for variants that responded to antagonists. Because multiple
mutations were detected in each mutant receptor recovered from the screen, site-directed mutagenesis was used to create
single-site mutant receptors. Three receptors containing mutations F55V, S219P, and S259P were analyzed for their
biological responses to various K-factor analogs and for their ligand binding profiles. Cells expressing each of the mutant
receptors responded to K-factor as well as or better than wild-type cells in a growth arrest assay. In contrast, the binding of K-
factor to the F55V and S219P mutant receptors was at least 10-fold reduced in comparison to wild-type receptor indicating a
complex non-linear correlation between binding affinity and biological activity. Cells expressing mutant receptors responded
to some normally inactive analogs in biological assays, despite the fact that these analogs had a low affinity for Ste2p. The
analysis of these mutant receptors confirms previous findings that the first and sixth transmembrane regions of Ste2p are
important for ligand interaction, ligand specificity, and/or receptor activation to initiate the signal transduction pathway.
Changes in binding affinity of pheromone analogs to wild-type and mutant receptors indicate that residue 55 of Ste2p is
involved with both ligand binding and signal transduction. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
The haploid mating types of the yeast Saccharo-
myces cerevisiae prepare for conjugation through a
signaling pathway initiated by the reciprocal action
of the di¡usible peptide pheromones a-factor and
K-factor [1]. These peptides speci¢cally bind to
G-protein-coupled receptors (GPCRs) expressed on
the cell surfaces of MATK and MATa cells, respec-
tively (for review see [2]). MATa cells express the K-
factor receptor [Ste2p], a GPCR encoded by the
STE2 gene [3^5]. The pheromone receptors of S.
cerevisiae share the structural motif of seven trans-
membrane (TM) regions with alternating intracellu-
lar and extracellular loops found in all members of
the GPCR superfamily (for review see [6]). The ap-
proximate placement of the seven TMs of Ste2p have
been experimentally corroborated using gene fusion
and protein reporter methodologies [7,8].
The structure of GPCRs is based partially on the
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low-resolution structure of the transmembrane core
of rhodoposin as proposed by Baldwin [9,10]. This
model is used by many workers as a point of refer-
ence in model building for other GPCR structures
and ligand binding sites. However, the structure of
GPCRs for peptide hormones is not known at
atomic resolution. The di⁄culty in generating crys-
tals of GPCRs suitable for X-ray crystallography has
prevented the shaping of a high-resolution structure
of GPCRs.
It is interesting to note that GPCRs have been
divided into families based on their sequence similar-
ity [11,12]. The class A family includes rhopdopsin-
like receptors with class B, C, and D representing
secretin-like, metabotropic glutamate, and phero-
mone receptors, respectively. Ste2p is in the class D
pheromone family with 9 other pheromone receptors
cloned from fungi. Some interesting features of Ste2p
in comparison to other GPCRs are the absence of
disul¢de bridges in a functional Ste2p and the pres-
ence of only three amino acids with ionizable side-
chains, R58, H94, and E143 that are predicted to be
deeply buried in the TM regions of the receptor.
Mutation of E143 to A143 results in a fully func-
tional receptor indicating that the presence of this
negative charge is not necessary for receptor function
[13]. Among the class D family, little work has been
done on the molecular structure of any member with
the exception of Ste2p.
For Ste2p, a number of receptor mutants have
been generated that contribute to our knowledge of
pheromone binding and G-protein coupling. Linker
insertion mutants [14], single residue substitution
mutations [13,15^19], and receptor chimeras between
S. cerevisiae and S. kluyveri STE2 genes [20,21] all
indicate that the K-factor binding site might include
determinants contributed by side chains from several
transmembrane segments and from extracellular
loops. Other mutagenic studies have indicated that
the I3 loop of Ste2p is important for interaction
with the G-protein [17^19]. Using a genetic screen
for second-site suppressors of mutant receptors, po-
tential contacts between TMs of Ste2p have been
uncovered [13]. In another study, a very interesting
mutant (P258L) caused the receptor to be constitu-
tively activated in the absence of pheromone [15].
In order to understand the molecular mechanism
governing ligand-induced receptor activation, struc-
tural information about the conformational di¡eren-
ces between the receptor resting and activated state
must be obtained [22^24]. A recent study using the
yeast K-factor^Ste2p model system indicated that ag-
onist binding led to an increased trypsin-accessibility
of the I3 loop, whereas antagonist occupation of
Ste2p led to a reduction of proteolytic cleavage with-
in this loop [25]. This analysis clearly indicated that
agonists and antagonists induced distinct conforma-
tional states that di¡er from the unbound form of
the receptor. A model hypothesized from these data
was that TM6, and perhaps TM5 and TM7, are dis-
placed via a piston-like movement upon agonist
binding so that buried residues of the I3 loop become
exposed intracellularly to the G-protein.
It is clear that additional experiments are required
to determine the ligand-binding site of K-factor with-
in its receptor. One approach we pursued involved
the search for mutant receptors that responded to K-
factor analogs that do not normally activate the
wild-type receptor. A number of antagonists were
available in our stocks of synthetic K-factor analogs
that were candidates for use in such a screen. We
report herein the identi¢cation of several mutants
with altered ligand binding properties. Biological re-
sponses and ligand binding studies with cells express-
ing these mutant receptors are presented.
2. Materials and methods
2.1. Strains
S. cerevisiae LM23-16az (16)[MATa ste2-i4 bar1
leu2 ura3 his4 lys5 met1 fus1 : :lacZ(URA3)] from
Lorraine Marsh, Albert Einstein College of Medi-
cine, New York, NY, was used as the recipient for
transformation with the STE2 randomly mutated li-
brary, and S. cerevisiae LM102 (16)[MATa ste2-dl
bar1 leu2 ura3 his4 trp1 met1 fus1: :lacZ(URA3)]
from Lorraine Marsh was used as the recipient of
the STE2 site-directed mutants and to measure pher-
omone-induced growth arrest (halo assay), phero-
mone-induced gene expression (lacZ assay) and pher-
omone binding. Strain LM23-16az carried a
mutation in the receptor gene rendering it inactive,
whereas strain LM102 was deleted for the receptor
gene. Both strains carried the bar1 mutant allele,
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thus inactivating the BAR1 protease responsible for
degradation of K-factor, and both strains contained a
fus1:lacZ gene serving as a pheromone-inducible re-
porter.
2.2. Peptide synthesis
[Nle12]K-factor, desTrp1[Ala3,Nle12]K-factor, des-
Trp1desHis2[Nle12]K-factor, [D-Ala3,Nle12]K-factor,
and [D-Ala10,Nle12]K-factor were all synthesized
using solid phase peptide synthesis as described pre-
viously [26^28]. All peptides used in bioassays were
s 98% homogeneous as judged by reversed-phase
HPLC in two eluent systems and capillary zone elec-
trophoresis. The [Nle12]K-factor analogs were devoid
of the parent compound as judged using HPLC anal-
ysis.
2.3. Primers and sequencing
All primers were purchased from BioServe Bio-
Technologies (Laurel, MD). Sequencing was carried
out manually using a dideoxy DNA sequencing kit
from United States Biochemical according to the
manufacturer’s instructions (Sequenase Version 2.0)
and by the DNA sequencing facility located on the
campus of the University of Tennessee.
2.4. Random mutagenesis of STE2 using a modi¢ed
PCR
Random mutations were introduced into STE2
by use of a modi¢ed version of a PCR based
random mutagenesis protocol [29] as described be-
low. STE2 was ampli¢ed using the primers XHOIA
(CATATCCAAGACTCGAGAATGTCTGATGC-
G) and XHOIB (CTACCACTACTCTCGAGAT-
GTTTATTATG) using the following conditions:
50 ng of pAB539 [3] as template; 50 nM each of
XHOIA and XHOIB primers; 200 WM MnCl2 ;
200 WM each of dCTP, dGTP, dTTP, and 40 WM
dATP; 1UPCR bu¡er (50 mM Tris, 500 Wg/ml
BSA, 0.5% Ficoll, 1 mM tartrazine, 2 mM MgCl2);
2.5 U Taq DNA polymerase (Promega) in 25 Wl total
volume. Hot start PCR was used for ampli¢cation by
heating the reaction mix (without Taq polymerase) to
94‡C for 5 min, transferring to ice for 5 min, and
then adding 2.5 U Taq polymerase and cycling
25 times at 94‡C for 30 s, 58‡C for 2 min, and
72‡C for 1.5 min. Point mutations in primer sequen-
ces (underlined) introduced £anking XhoI restriction
sites that allowed for subcloning of mutagenic PCR
products into the unique SalI site of the vector
pAD54 [30] to produce a series of yeast expression
vectors (pSTEAD) containing a library of mutant
receptor genes. In this plasmid the receptor gene
was under the control of the constitutive promoter
ADH1p, and the plasmid replicated under control of
the 2 W element.
2.5. FUS1-lacZ screen for antagonist responsive
mutant receptors
The pSTEAD library of plasmids was transformed
according to standard protocol [31] into yeast strain
LM23-16az [16], plated on synthetic dextrose mini-
mal medium supplemented with lysine and methio-
nine (SD+KM) and grown at 30‡C for 72 h. LacZ
induction was assayed as previously described [16].
Transformant colonies were replica plated onto
SD+KM plates overlaid with ¢lters (Whatman no.
50) and with or without 10 Wg/ml desTrp1desHis2-
[Nle12]K-factor antagonist [26] and incubated for 6 h
at 30‡C. Filters were quick-frozen in liquid nitrogen
for 20 s and transferred to a second ¢lter (Whatman
no. 3) that had been soaked with 2.5 ml Z-bu¡er
(60 mM Na2HPO4W7H2O, 40 mM NaH2PO4WH2O,
10 mM KCl, 1 mM MgSO4W7H2O, 50 mM L-mercap-
toethanol, pH 7.0) containing 0.03% X-gal. The ¢l-
ters were incubated at 30‡C for 1^3 h to allow for
any blue color development from L-galactosidase
production. Filters were aligned with the original
transformant plates and colonies corresponding to
replicated colonies that turned blue were isolated
for further testing. Plasmids from the transformed
yeast colonies that demonstrated unusual pheno-
type(s) to [Nle12]K-factor and/or antagonist were iso-
lated [32], ampli¢ed in E. coli, and puri¢ed using a
plasmid maxiprep kit (Qiagen) as per manufacturer’s
instructions.
2.6. Construction of expression vector for site-directed
mutagenesis
A yeast/bacterial shuttle vector (pGA314.WT) was
constructed by starting with the vector pRS314 [33]
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linearized with SpeI (New England Biolabs, NEB)
and puri¢ed with the Wizard DNA clean-up kit
according to manufacturers protocol (Promega). A
1.8 kb PCR fragment containing the STE2 ORF
plus 316 bp upstream promoter region from
the start ATG and 163 bp downstream region from
the stop codon was ampli¢ed from the vector
template pAB539 [3] using the primers SPEIA
(GCTTTGCAATGAAACACTAGTATCCGCTAA-
G) and SPEIB (GTGGTTTCTAC CACTAGTTAC-
GAGATGTTTATTATG). The PCR conditions used
were as follows: 40 ng pAB539, 100 nM each primers
SPEIA and SPEIB, mix of 200 WM each of dNTP,
1UDeepVent polymerase bu¡er (10 mM KCl, 10 mM
(NH4)2SO4, 20 mM Tris-HCl (pH 8.8), 2 mM
MgSO4, 0.1% Triton X-100), 1 U DeepVent DNA
polymerase (NEB), for 25 cycles of 94‡C (1 min),
46‡C (2 min), 72‡C (3 min) with a ¢nal extension
of 72‡C for 10 min. Point mutations (underlined in
primer sequence) introduce SpeI restriction sites into
the ends of the PCR fragment. PCR fragments were
subsequently digested with SpeI and puri¢ed with the
Wizard PCR preps DNA puri¢cation system (Prom-
ega). PCR fragment and linear pRS314 vector were
ligated together using the standard protocol accom-
panying the Ligator rapid DNA ligation and screen-
ing kit (Epicenter Technologies) producing the vector
pGA314.WT. The entire STE2 gene and £anking
regions was sequenced and con¢rmed that the sub-
cloned region was wild-type sequence with no spurious
mutations. In this plasmid, the STE2 gene was under
control of its own promoter, and the plasmid repli-
cated under control of the CEN6/ARSH4 element.
2.7. Site-directed mutagenesis of STE2
Site-directed mutagenesis of STE2 was carried out
using a modi¢ed version of overlap extension PCR
[34]. The ¢rst round of ampli¢cation required 200 ng
pGA314.WT DNA, 5 WM dNTPs, 1 WM primer A or
B, 1 WM of each mutagenic primer, 1UTaq DNA
polymerase bu¡er (50 mM KCl, 10 mM Tris-HCl,
0.1% Triton X-100, 2 mM MgCl2, NEB), and 2.5 U
Taq DNA polymerase (NEB) in a total volume of
100 Wl for 25 cycles of 94‡C (1 min), 50‡C (2 min),
and 72‡C (3 min). Fragments generated during the
¢rst round of PCR were gel puri¢ed using the Gene-
clean I kit (Bio101) and used as template DNA for
a second round of PCR-overlap extension mutagen-
esis. The second round of ampli¢cation was per-
formed using 200 ng of the 5P-half mutagenic frag-
ment, 200 ng of the 3P-half mutagenic fragment,
1UTaq DNA polymerase bu¡er, 100 WM dNTPs,
and 1 U Taq DNA polymerase in a total volume
of 10 Wl for 10 cycles of 94‡C (1 min), 55‡C
(2 min), and 72‡C (3 min). A third round of ampli-
¢cation was performed to produce the full length
STE2 gene with point mutations (underlined in
primer sequences below) that introduce single amino
acid substitutions in the translated protein product.
Conditions for the third round of ampli¢cation were
1 Wl of round 2 reaction mix, 1.0 WM primer A,
1.0 WM primer B, 1UTaq DNA polymerase bu¡er,
5 WM dNTPs, and 2.5 U Taq DNA polymerase in a
total volume of 100 Wl for 30 cycles of 94‡C (1 min),
50‡C (2 min), and 72‡C (3 min).
Full-length third round PCR reaction products
were subcloned into the vector pCR2.1 (Invitrogen
TA cloning kit) and ampli¢ed in Escherichia coli
strain DH5K. Bacterial transformants were randomly
chosen and plasmid DNA was isolated from each
[35]. Insert-containing plasmids were digested with
EcoRI and the 1.8 kb STE2 gene fragment was
isolated using the Geneclean I DNA puri¢cation
kit and subcloned into the unique EcoRI site of
pRS314 to produce the plasmids pGA314.F55V,
pGA314.S219P, and pGA314.S259P (pGA314.WT
vector with TRP and URA as selectable markers
that now contains a STE2 gene with the designated
mutation).
Primer pairs used for the initial round of am-
pli¢cation reactions to introduce single point muta-
tions were primer A (GGATAACAATTTCACAC-
AGG) with primer F55VF (GGCCATTATGGTTG-
GTGTCAG), primer A with primer S259PF (GTTG-
GTTCCACCGATAAT ATT), primer A with primer
S219PF (GCATCCT CAATAAACTTTATGCCA-
TTTGTCCTGGTAGTTAAATTGATTTTAGC),
primer B (TCGCTATTACGCCAGCTGG) with
primer F55VR (CTGACACCAACCATA ATGGCC),
primer B with primer S259PR (AATATT-
ATCGGTGGAACCAAC), primer B with primer
S219PR (GCTAAAATCAATTTAACTACCAGG-
ACAAA TGGCATAAAGTTTATTGAGGATGC).
All of the mutant receptor genes were sequenced
twice to ensure that the sequences were identical to
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the published wild-type sequence of STE2 with the
exception of the designed mutant nucleotide changes.
2.8. Growth arrest (halo) assay
SD medium [36] supplemented with histidine
(20 Wg/ml), leucine (30 Wg/ml) and methionine
(20 Wg/ml) was overlaid with 4 ml of S. cerevisiae
LM102 (2.5U105 cells/ml of Nobel agar) trans-
formed with various plasmids containing wild-type
or mutant STE2. Filter disks (sterile blanks from
Difco), 8 mm in diameter, were placed on the over-
lay, and 10 Wl portions of peptide solutions at vari-
ous concentrations were placed on the disks. The
plates were incubated at 30‡C for 24^36 h and then
observed for clear zones (halos) around the disks.
The data were expressed as the diameter of the
halo including the diameter of the disk. The mini-
mum value for growth arrest is 9 mm, which repre-
sents the disk diameter (8 mm) and a small zone of
inhibition. [Nle12]K-factor, an isosteric analog that is
equally active to the wild-type pheromone [37] was
used as a control in all bioactivity assays and in
receptor binding. All assays were repeated at least
three times with no more than a 2 mm variation in
halo size for a particular amount of peptide. The
data were plotted as halo size versus the amount of
pheromone added to the lawn and linearized by re-
gression analysis. To compare the relative activities
of di¡erent peptides with di¡erent receptors, the
amount of peptide causing a halo size of 15 mm
was determined from the regression line. At least
two dose response values were above and below the
15 mm intersection point on the regression line mak-
ing extrapolation of the data unnecessary. In addi-
tion, the slopes of dose response curves for the di¡er-
ent receptors were nearly identical validating the
comparisons among receptors for di¡erent analogs.
Di¡erences in di¡usion of the various analogs in the
agar medium did not contribute to the di¡erences in
the biological activities in the halo assay. Similar
trends were obtained for these analogs when activities
were ranked within an assay as measured by the halo
or gene (FUS1-LacZ) induction. In the FUS1-LacZ
assay, cells were suspended in liquid medium and
di¡usion through agar played no role in the activity
of the soluble pheromones. Further evidence that
di¡usion rates do not determine bioactivity in the
halo assay is given by the fact that there is no corre-
lation between bioactivity and peptide hydrophobic-
ity as measured by KP values on HPLC columns [27].
2.9. E¡ect of K-factor analogs on gene induction
S. cerevisiae LM102 carries a FUS1 gene that is
inducible by mating pheromone and fused to the
gene encoding L-galactosidase as a reporter. Cells
were grown overnight in SD at 30‡C to 5U106
cells/ml, harvested by centrifugation, resuspended in
fresh medium, and allowed to grow at 30‡C until
they had doubled in number. Induction was per-
formed by adding 0.5 ml of peptide at various con-
centrations to 4.5 ml of concentrated cells (1U108
cells/ml). The suspensions were vortexed and placed
at 30‡C with shaking for 2 h. After this time, cells
were harvested by centrifugation, each pellet was re-
suspended, and assays were carried out for L-galac-
tosidase in triplicate by a recently modi¢ed [38]
standard protocol [39,40]. The experiments were re-
peated at least twice for each analog with the values
plotted representing an average of these determina-
tions.
2.10. Antagonism and synergism assays
The halo assay was used to determine whether
analogs that had no growth arrest activity by them-
selves were capable of antagonizing (interfering with
activity by agonists) or synergizing (enhancing activ-
ity of agonists) activity of [Nle12]K-factor [26]. Lawns
of LM102 were overlaid onto SD plates as described
in the growth arrest assay. Sterile disks were placed
adjacent to each other so that the disk containing the
test peptide would lie at the periphery of the halo
formed by [Nle12]K-factor. One disk was impregnated
with 1 Wg of [Nle12]K-factor in 10 Wl H2O, and the
other disk was impregnated with various amounts of
the test peptide in 10 Wl H2O. Plates were incubated
as described in the growth arrest assay and the e¡ects
on halo formation noted.
2.11. HPLC puri¢cation of [3H]K-factor
Synthetic [Nle12]K-factor was labeled by reduction
of dehydroproline containing K-factor by the TR3
hydrogenation procedure of Amersham International
BBAMCR 14381 11-11-98
M.G. Abel et al. / Biochimica et Biophysica Acta 1448 (1998) 12^2616
as described previously [37]. Unpuri¢ed, labeled pep-
tide (dissolved in ethanol/water 1:1) was dried in
vacuo, redissolved in sterile water and puri¢ed by
HPLC using a Waters W Bondapak C18 column
(3.9U300 mm) on a Beckman System Gold HPLC.
The peptide solution was injected into the HPLC and
eluted with a water/acetonitrile gradient from 0 to
40% acetonitrile. Fractions containing peptide elut-
ing from the column similarly to unlabeled K-factor
(elution at 32.3% CH3CN) were collected and
counted for radioactivity in a scintillation counter.
All collected fractions were dried, resuspended in
storage bu¡er (1 mM methionine, 0.03% tri£uoroace-
tic acid, 20% ethanol), combined, and the concentra-
tion and speci¢c activity of the puri¢ed labeled pep-
tide was determined.
2.12. Binding competition assay
This assay was performed using membranes of
strain LM102 and HPLC-puri¢ed [3H-Nle12]K-factor
(see above) as described previously [41]. Binding of
labeled K-factor to ¢lters in the absence of mem-
branes was less than 20 cpm. Speci¢c binding is de-
¢ned as (mean bound cpm/total mean cpm)U100.
Mean bound cpm is the average of four determina-
tions for each binding point for each analog and
total mean cpm is the average of four determinations
of the total counts incubated with each analog. Re-
sults for each analog were expressed as a percent of
total binding in the absence of the analog. Each
binding assay was carried out at least two times
with virtually identical curves obtained. The Ki val-
ues were calculated by dividing the experimentally
determined concentration giving 50% binding dis-
placement by (1+ HT/Kd) where HT = concentration
of radiolabel and Kd = dissociation constant of radio-
label [42].
2.13. Western blot
Equal amounts of solubilized membrane proteins
(5 Wg) were resolved by SDS-PAGE (10%), electro-
phoretically transferred to immobilon P membrane
(Millipore) and probed with anti-N-terminal-Ste2p
antibodies provided by James Konopka, SUNY
Stony Brook [43]. The resulting immune complexes
were detected by incubation with 1:3,000 dilution of
horseradish peroxidase-conjugated goat anti-rabbit
antibodies, and visualized by chemiluminescence
(ECL kit, Amersham).
3. Results
3.1. Random mutagenesis of STE2 and sequence
analysis
The plasmid pAB539 [3] was used as the template
DNA for PCR-based, random mutagenesis of the
STE2 gene. Saccharomyces cerevisiae strain LM23-
16az (a MATa yeast strain that expresses a non-func-
tional K-factor receptor) was transformed with the
library of mutant STE2-containing plasmids and
screened for ligand-dependent biological response
to desTrp1desHis2[Nle12]K-factor, an antagonist pep-
tide [26], by FUS1-lacZ induction. Approximately
40 000 colonies were screened and a total of 144
FUS1-lacZ positive clones were isolated. These
clones were re-tested for FUS1-lacZ induction and
83 false-positive clones that did not respond to
antagonist were identi¢ed and discarded. The re-
maining 61 L-galactosidase-positive colonies were
individually plated as lawns on selective medium
and tested for growth arrest response to 3 Wg of
[Nle12]K-factor, 10 Wg of the antagonist desTrp1-
desHis2[Nle12]K-factor, and 10 Wg of the antagonist
desTrp1[Ala3,Nle12]K-factor [44]. Eighteen colonies
demonstrated varying degrees of growth arrest
(zones of growth inhibition from 9 to 21 mm) to
both antagonists and [Nle12]K-factor (e.g. MR007
and MR012, Table 1), and 20 colonies (e.g.
MR097, Table 1) demonstrated no growth arrest re-
sponse to either of the antagonists or [Nle12]K-factor.
The remaining isolates responded to [Nle12]K-factor
to varying degrees (9^25 mm diameter zones of
growth inhibition), but did not respond to either an-
tagonist (e.g. MR019 and MR025, Table 1) or re-
sponded only to antagonists (e.g. MR131, Table 1).
Plasmid DNA from representatives of each pheno-
type class (MR007, MR012, MR019, MR025,
MR097, and MR131) was puri¢ed and STE2 se-
quenced to identify the mutated residues (Table 1).
Each of the mutated STE2 genes contained between
10 and 19 bp changes that translated into 5^10 res-
idue mutations per receptor protein. Due to the dif-
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¢culties in interpreting phenotypic changes in pher-
omone response with receptors containing multiple
mutations, we decided to generate site-speci¢c mu-
tants based on results obtained in the multiply mu-
tated receptors produced by PCR mutagenesis.
3.2. Site-directed mutagenesis of STE2
Speci¢c residues identi¢ed during the random mu-
tagenesis of the STE2 gene were targeted for site-
directed mutagenesis based on three criteria: (1) the
residue was observed to be changed in receptors with
an antagonist-responsive growth arrest phenotype;
(2) the residue was located in a transmembrane do-
main; and (3) the residue was in close proximity to
previously described receptor mutations demonstrat-
ing phenotypes of altered ligand interactions [15,16].
PCR based site-directed mutagenesis (see Section 2)
of wild-type STE2 was carried out to produce 3 mu-
tant receptors each expressing one of the following
mutations: F55V (TM domain 1), S219P (TM do-
main 5), or S259P (TM domain 6).
Table 1
Sequence and growth arrest response of mutant K-factor receptors selected in screen
Mutant Mutation Halo response to:
N-Terminal domain
(residues 1^50)
Middle domain
(residues 51^299)
C-Terminal domain
(residues 300^431)
Antagonista K-Factor
MR007 None N84D I308G + +
M165T F327S
F182L E403G
N216S
I230T
D242G
MR012 None S259P A369G + +
I263V M409T
D417G
MR019 E40G L93F N375S 3 +
Q149R D417G
K422E
F423S
MR025 F38L R76G N301S 3 +
G156S T354R
M165I K374N
L255M G402A
S267G
T278S
MR097 S28F F116L K304I 3 3
N46D L284P K374E
L380S
T382A
MR131 None F55V T313S + 3
N132S R318G
I142N L324P
S219P N334D
R343S
D357G
adesTrp1desHis2[Nle12]K-factor and desTrp1[Ala3,Nle12]K-factor were the antagonists used in the screening.
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3.3. Growth arrest response of mutant K-factor
receptors to [Nle12]K-factor and various analogs
The three mutant receptors were expressed in
LM102 and tested for their growth arrest response
to [Nle12]K-factor and K-factor analogs (Table 2).
Three peptides previously demonstrated to be antag-
onists [26,27,44] desTrp1desHis2[Nle12]K-factor,
desTrp1[Ala3,Nle12]K-factor, and [D-Ala3,Nle12]K-fac-
tor, and one synergistic peptide [27], [D-
Ala10,Nle12]K-factor, were used to challenge mutant
receptors. As previously shown, none of these ana-
logs elicited a growth arrest response from a cell
expressing a wild-type receptor. All responses to all
peptides were ligand-dependent (constitutively re-
sponding mutant receptors were not isolated or ob-
served).
Each of the strains carrying mutant receptors was
induced to form a 15 mm halo by less K-factor than
that needed to induce a 15 mm halo in the wild-type
receptor strain. Thus, the mutant receptor responded
better than the wild-type receptor to K-factor itself in
this assay (Table 2). The largest increase in sensitivity
(V2-fold) was found with S259P. The response of
the mutants was greater to K-factor at each amount
tested from 0.05 to 10 Wg/ml of K-factor (data not
Table 3
Pro¢le of peptide activities in wild-type and mutant receptorsa
Ste2p expressed Activities of peptides tested
K-Factorb Antagonist 1c Antagonist 2d Antagonist 3e Synergistf
Wild-type Agonist Antagonist Antagonist Antagonist Synergist
F55V Agonist Antagonist to D-Ala10,
but not to K-factor
Not antagonistic to
K-factor or D-Ala10
Not antagonistic to
K-factor or D-Ala10
Agonist
S219P Agonist Antagonist to all agonists Agonist Antagonist to all agonists Agonist
S259P Agonist Agonist Agonist Agonist Agonist
aThe agonist activity is seen in both the growth arrest (Table 2) and Fus1-lacZ assay (Table 4).
b[Nle12]K-factor.
cdesTrp1desHis2[Nle12]K-factor.
ddesTrp1[Ala3,Nle12]K-factor.
e[D-Ala3,Nle12]K-factor.
f [D-Ala10,Nle12]K-factor.
Table 2
Growth arrest response to K-factor and K-factor analogs in cells expressing various receptors
Ste2p expressed Amount of peptide (Wg) for 15 mm haloa
K-Factorb Antagonist 1c Antagonist 2d Antagonist 3e Synergistf
Wild-type 0.33 (1.0) s 20g s 20 s 20 s 20
F55V 0.26 (1.27) s 20 s 20 s 20 1.38 (0.24)
S219P 0.17 (1.94) s 20 1.84 (0.18) s 20 0.45 (0.73)
S259P 0.15 (2.2) 5.75 (0.06) 2.5 (0.13) 1.96 (0.17) 3.55 (0.09)
aThe number in parentheses is the ratio of the amount of peptide required for a 15 mm halo compared to the amount (0.33 Wg) of
K-factor required for a 15 mm halo in the wild-type receptor.
b[Nle12]K-factor.
cdesTrp1desHis2[Nle12]K-factor.
ddesTrp1[Ala3,Nle12]K-factor.
e[D-Ala3,Nle12]K-factor.
f [D-Ala10,Nle12]K-factor.
g20 Wg was highest amount of peptide tested.
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shown). Receptor F55V did not respond to any an-
tagonist, but the synergist analog [D-Ala10,Nle12]K-
factor became a weak agonist for this mutant re-
ceptor; it took 1.38 Wg of analog to produce a
15 mm halo in F55V, whereas only 0.33 Wg of K-
factor was required to induce this size halo in the
wild-type receptor. Receptor S219P responded well
to the synergist, poorly to one of the antagonists
(desTrp1[Ala3,Nle12]K-factor), and not at all to the
other two antagonists tested. Receptor S259P, which
was the most responsive to K-factor, responded to all
the antagonists and synergists tested, albeit rather
poorly. The failure of F55V to respond to any of
the antagonists, despite the fact that the screen im-
plicated this as a potential residue for antagonist
responsiveness, indicates that either the other muta-
tions of the receptor or a combination of these other
mutations and F55V caused the antagonist response
in the screen.
When a peptide showed no agonist activity to an
expressed receptor, the peptide was tested for
antagonistic activity against peptides that were ago-
nists for that receptor. The results of these assays are
summarized in Table 3. For clarity, the table also
re£ects the results of Table 2 as to the activity of
active peptides. The pattern of cross antagonism is
complex. For example, desTrp1desHis2[Nle12]K-fac-
tor is antagonistic to [D-Ala10,Nle12]K-factor, but
not K-factor in the F55V receptor whereas it is an-
tagonistic to all agonists in the S219P receptor.
DesTrp1 [Ala3,Nle12]K-factor and [D-Ala3,Nle12]K-
factor are not antagonists in the F55V receptor,
but [D-Ala3,Nle12]K-factor was an antagonist to all
agonists for the S219P receptor. As indicated by
the competition binding assays, the above character-
istics are not simply related to the relative a⁄nities
of these peptides for the various receptors (see be-
low).
3.4. Expression of receptor protein in mutants
A direct measurement of receptor protein was car-
ried out to determine whether any of the mutations
a¡ected receptor biosynthesis or transport to the
membrane. Cells expressing the various mutant
Ste2p constructs were grown, membranes prepared,
and proteins separated by SDS-PAGE according to
standard conditions for measurement of Ste2p ex-
pression in S. cerevisiae. Ample amounts of receptor
were detected in Western blots of the wild-type and
Table 4
Gene induction by various peptides in wild-type and receptor mutants
Ste2p expressed Gene induction activity of peptides testeda
K-Factorb Antagonist 1c Antagonist 2d Antagonist 3e Synergistf
Wild-type 24.0 þ 1.9 (1.0) 0.3 (6 0.03) 0.2 (6 0.03) 0.1 (6 0.03) 0.35 (6 0.03)
F55V 19.2 þ 1.8 (0.8) 0.3 (6 0.03) 0.5 (6 0.03) 0.3 (6 0.03) 20.00 þ 2.8 (0.83)
S219P 15.0 þ 1.5 (0.63) 0.6 (6 0.03) 6.0 þ 0.8 (0.25) 0.6 (6 0.03) 13.00 þ 1.1 (0.54)
S259P 24.0 þ 2.2 (1.0) 15.5 þ 2 (0.65) 17.0 þ 1.6 (0.7) 14.9 þ 0.8 (0.62) 18.00 þ 1.3 (0.75)
aAll peptides were added at 10 WM and the lacZ activity in Miller units was determined as in Section 2. The standard error of the
mean is indicated, and the number in parentheses is the ratio of the amount of lacZ compared to the amount (24 Miller units) in-
duced by K-factor in the wild-type receptor. The basal activity for all peptides and mutants was 0.1 Miller units.
b[Nle12]K-factor.
cdesTrp1desHis2[Nle12]K-factor.
ddesTrp1[Ala3,Nle12]K-factor.
e[D-Ala3,Nle12]K-factor.
f [D-Ala10,Nle12]K-factor.
Fig. 1. Western blots of cells expressing wild-type and mutant
receptors. WT, wild-type cells ; F55V, S219P, and S259P, cells
expressing Ste2p carrying the F55V, S219P, and S259P muta-
tions, respectively. The molecular weight markers are shown for
proteins of 52 and 39 kDa, and the position where Ste2p is pre-
dicted to migrate is indicated by an arrow.
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mutant receptors F55V and S219P (Fig. 1). The ap-
parent doublet form of the receptor has been ob-
served by others using various antibody preparations
[15,25,40,42]. In contrast to visualization of Ste2p in
mutants F55V and S219P, the S259P receptor was
practically undetectable despite the good K-factor re-
sponse in cells expressing S259P. The data repre-
sented in Fig. 1, along with the inability to obtain
a measurable binding of K-factor to cells expressing
S259P, may be attributed to the instability of the
S259P receptor or to other factors as discussed be-
low.
3.5. Mutant receptor signaling as indicated by
induction of pheromone-responsive gene to
K-factor and K-factor analogs
LacZ activity was measured in response to a single
concentration (10 WM) of various peptides added to
cultures expressing wild-type and mutant receptors
(Table 4). At this concentration K-factor induced
near maximal activity in cells expressing wild-type
Ste2p. In general, the pattern of FUS1-lacZ gene
induction is similar to that of the growth arrest re-
sponse for all receptors and peptides. In all cases,
Fig. 2. Dose response to K-factor and K-factor analogs in wild-type and mutant receptors determined by reporter gene lacZ. The
wild-type, F55V, S219P, and S259P receptors are shown in separate panels indicted on the ¢gure. Responses to [Nle12]K-factor (a),
desTrp1,desHis2[Nle12]K-factor (b), desTrp1[Ala3, Nle12]K-factor (P), [D-Ala3,Nle12]K-factor (S), and [D-Ala10,Nle12]K-factor (E) are
shown at various amounts of peptide.
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peptides exhibiting no activity in the growth arrest
assay induce less than 3% of the lacZ activity in-
duced by K-factor. Where activity was observed in
the growth arrest assay, gene induction was also ob-
served. For example, the D-Ala10 analog was an ago-
nist against all mutant receptors in both assays.
However, some subtle di¡erences between the growth
arrest assay and the gene induction assay are noted:
(1) in the growth arrest assay, K-factor was more
active in the mutant receptors than in the wild-type
receptor, whereas K-factor was most active for the
wild-type receptor in the gene induction assay; (2)
all analogs appeared to be more active in the gene
induction assay than in the growth arrest assay for
the S259P receptor; and (3) the D-Ala10 analog was
more active for the F55V and S259P receptor mu-
tants in the gene induction assay as compared to the
growth arrest assay. In order to carry out a more
detailed study, a dose response of lacZ activity to
various amounts of peptides was determined (Fig.
2). The wild-type receptor did not transduce the sig-
nal to the reporter gene at any concentration of an-
tagonist or synergist tested (Fig. 2, WT). Further-
more, the response curves of F55V and S219P
indicated only partial induction of the lacZ gene
even at pheromone concentrations as high as
10 WM. Thus, while the mutant receptors respond
to certain compounds that were inactive with wild-
type Ste2p, these receptors cannot trigger a complete
signal upon activation by these compounds or K-fac-
tor.
3.6. Binding competition assays
Binding of peptides to the wild-type and two mu-
tant receptors was determined by competition assays
on isolated membranes. The binding curves for the
K-factor analogs demonstrate that many analogs do
not reach a level of 50% competition, even at the
highest concentrations used in the assay. This is
likely due to the poor binding a⁄nity of these pep-
tides at the concentrations attainable for testing
(Fig. 3). The calculated Ki values indicate that bind-
Fig. 3. Competition binding assays of wild-type and mutant re-
ceptors to K-factor and K-factor analogs. The wild-type, F55V,
and S219P receptors are shown in separate panels indicated on
the ¢gure. Binding competition to various amounts of peptide
are indicated with [Nle12]K-factor (a), desTrp1,desHis2[Nle12]K-
factor (b), desTrp1[Ala3, Nle12]K-factor (P), [D-Ala3, Nle12]K-
factor (S), and [D-Ala10, Nle12]K-factor (E).
6
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ing of K-factor to the F55V and S219P receptors was
about 10-fold less than its binding to the wild-type
receptor (Table 5). As seen in previous reports
[26,27], the competition of the synergist for K-factor
binding to the wild-type receptor was not detectable,
but the synergist did compete with the K-factor bind-
ing site in F55V. The synergist had a 10-fold lower
a⁄nity than K-factor for the F55V receptor. We were
not able to measure binding to the S259P receptor.
Even at high concentrations of [3H]K-factor, the
amount of radioactive K-factor associated with mem-
branes from cells expressing the S259P receptor was
not above background levels. Attempts to measure
binding with whole cells were unsuccessful as well
using methods previously employed by us and others
[5,37]. The inability to measure binding to the S259P
receptor may be related to the instability of this re-
ceptor as re£ected by the barely detectable amount
of Ste2p in Western blots (Fig. 1 and see Section 4).
The Ki values for the antagonists to the wild-type
receptor were similar to values obtained for measure-
ments using whole cells and STE2 expressed from its
natural chromosomal site under its natural promoter
[27,37]. None of the peptides formerly identi¢ed as
antagonists for wild-type Ste2p bound with high af-
¢nity to any of the mutant receptors (Table 5, Fig.
3). This was despite the fact that several of these
peptides were either weak agonists or antagonists
for these mutant receptors in the halo or gene induc-
tion assays (Tables 2 and 4).
4. Discussion
We have generated mutant K-factor receptors al-
tered in their response to various K-factor analogs
using PCR-based random mutagenesis and site-di-
rected mutagenesis. Three receptors containing mu-
tations F55V, S219P, and S259P were analyzed for
their biological responses to K-factor antagonists and
an K-factor synergist and for their ligand binding
pro¢les. Analysis of these mutant receptors impli-
cates the ¢rst and sixth transmembrane regions of
Ste2p as important for ligand interaction, ligand spe-
ci¢city, and/or receptor activation to initiate the sig-
nal transduction pathway. Changes in binding a⁄n-
ity of pheromone analogs to wild-type and mutant
receptors indicate that residue 55 of Ste2p is involved
with both ligand binding and signal transduction.
Initially, the K-factor receptor was mutated utiliz-
ing the intrinsic error rate of the Taq DNA polymer-
ase in a modi¢ed PCR protocol [29] in an attempt to
introduce single mutations randomly throughout the
gene. The screen was successful in that we were able
to introduce random mutations in the STE2 gene
yielding antagonist-responsive receptors, but the mu-
tant STE2 genes recovered from colonies responding
to an K-factor antagonist contained 5^10 residue
substitutions per receptor. While information con-
cerning the roles of speci¢c residues of the receptor
could not be elucidated from mutant receptors con-
taining multiple mutations, these experiments pro-
Table 5
Competition binding assay
Ste2p expressed Binding constants of peptides testeda
K-Factorb Antagonist 1c Antagonist 2d Antagonist 3e Synergistf
Wild-type 1.8 þ 0.2 125 þ 10 1 750 þ 100 1 050 þ 50 s 10 000
F55V 19.4 þ 0.4 V10 000 s 10 000 s 10 000 210 þ 10
S219P 14.6 þ 2.6 s 10 000 s 10 000 s 10 000 s 10 000
S259P No detectable binding under the
conditions tested.
aThe values shown in the table are the Ki values (U1038 M). The standard error of the mean is indicated for quadruplicate assays.
b[Nle12]K-factor.
cdesTrp1desHis2[Nle12]K-factor.
ddesTrp1[Ala3,Nle12]K-factor.
e[D-Ala3,Nle12]K-factor.
f [D-Ala10,Nle12]K-factor.
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vided guidance for the subsequent generation of site-
directed, single-residue mutants.
The F55V mutation found in the random screen
was chosen for further study due its proximity to a
mutation in the adjacent methionine (M54I) residue
described by Marsh [16]. The M54I receptor re-
sponded poorly to desTrp1[Ala3]K-factor in compar-
ison to its response to K-factor in the FUS1-lacZ
assay, and this receptor (M54I) responded equally
as well as the wild-type receptor to K-factor in a
growth arrest assay. These and other results allowed
Marsh to conclude that the M54I mutation appeared
to a¡ect ligand speci¢city only [16]. In our studies,
the F55V mutant receptor responded to the synergis-
tic analog [D-Ala10,Nle12]K-factor and also to
[Nle12]K-factor, but there was no response to any
of three antagonists tested. It is interesting, and per-
haps indicative of subtle interactions between ligand
residues and receptor residues that are adjacent in
the primary sequence, that the analog
desTrp1[Ala3]K-factor, an antagonist to the wild-
type receptor, was an agonist to M54I, but not to
F55V. In the wild-type receptor, the D-Ala10 analog
did not have any activity in the growth arrest assay
or FUS1-lacZ on its own, but did enhance the po-
tency of [Nle12]K-factor in both assays when incu-
bated together [27]. The nature of this e¡ect for the
D-Ala10 analog might be explained by a mutation in
receptor residue 55 that normally interacts directly
with the native ligand.
Although the binding of K-factor itself is decreased
in the F55V mutant, the binding of the D-Ala10 ana-
log is greatly increased over its binding to the wild-
type receptor (Table 5). Previous results indicated
that the carboxyl terminus of K-factor is extremely
important for binding [27]. Changing Tyr13 to Ala13
resulted in almost a 500-fold decrease in a⁄nity for
wild-type Ste2p. In addition, results with chimeric
receptors from S. cerevisiae and S. kluyveri indicated
that there may be an interaction between the side
chain of residue 10 [Gln] of K-factor and residues
45^47 of the receptor [21]. As stated above, residue
54 of Ste2p has also been implicated in pheromone
binding [16]. These results allow us to hypothesize
that one aspect of the binding of K-factor to Ste2p
involves interactions of the carboxyl terminus of the
pheromone (residues 10^13) with residues near the
interface between the extracellular N-terminus and
the ¢rst transmembrane helix of Ste2p. If this hy-
pothesis is correct, then the Tyr side chain might
interact with F55 via aromatic stacking. In addition,
since [Phe13]K-factor has virtually no activity [45], the
OH of Tyr is likely involved in some hydrogen bond-
ing interaction.
According to the data discussed above, it is rea-
sonable that the D-Ala10 analog does not bind to
wild-type Ste2p. Change in chirality of residue
10 would result in a major change in the orientation
of the carboxyl terminus of K-factor and the remain-
der of the pheromone. It is interesting that the F55V
mutation binds D-Ala10 K-factor only one order of
magnitude less strongly then K-factor and that this
binding results in signal transduction. This result
suggests that the F55V receptor has a signi¢cantly
di¡erent binding site than that of the wild-type re-
ceptor and that the replacement of valine for phenyl-
alanine probably causes more than a simple change
in the local environment of this receptor residue. The
fact that F55V exhibits a 10-fold lower a⁄nity for
[Nle12]K-factor and that all of the antagonists have
very low a⁄nity for F55V would be consistent with
the conclusion that the binding site changes dramat-
ically.
The S219P mutation in the 5th TM was interesting
because of the nature of the mutation (a serine to a
proline residue) and the location in the protein (TM
domain contiguous with the 3rd cytoplasmic loop).
Ste2p with mutations in TM5 have been identi¢ed
previously [16]. One such receptor had the mutation
of A229V and another contained the two mutations
S145L and S219L. These mutant receptors responded
like the M54I mutant receptor to both K-factor and
an antagonist. In our studies, cells expressing the
S219P receptor responded to one antagonist and a
synergist in the growth arrest and FUS1-LacZ as-
says, but these analogs did not compete well, even
at high concentrations, with K-factor binding to the
S219P receptor. This lack of correlation between
binding and the degree activation of biological re-
sponses of various mutants has been observed previ-
ously [16,26,27].
The S259P mutation produces a receptor that re-
sponds to all antagonists and the synergist peptide
tested. Residue 259 is adjacent to another proline at
258, and the introduction of two prolines in the 6th
transmembrane domain may confer a drastic confor-
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mational change allowing normally weakly binding
ligands to occupy the binding site of the receptor
and trigger a response. A constitutively active recep-
tor mutant was reported that contains a mutation
changing P258 to leucine [15]. The introduction of
the leucine residue may have locked the receptor in
the ‘on’ conformation and thus cause the constitutive
phenotype observed. Although the S259P mutant is
not a constitutively active receptor in our strain
background, in other strain backgrounds, it does ap-
pear to be constitutive (M. Dumont, personal com-
munication). The introduction of a proline adjacent
to the naturally occurring proline at residue 258
might remove some stabilizing conformational re-
straints allowing weakly interacting ligands to pro-
mote transition of the receptor from an inactive to
an active state.
The inability to determine a measurable binding of
K-factor to the S259P receptor may be attributable to
the instability of this receptor. Although the receptor
is stable enough to be responsive to peptides in var-
ious biological assays, when cells or membranes are
subjected to the treatments used for binding studies
or for gel electrophoresis, the protein is apparently
not stable enough to be detected. Recently, structural
instability of a constitutively active G-protein-
coupled receptor was reported [46]. In this study,
the L2-adrenergic receptor showed a 4-fold increase
in the rate of denaturation at 37‡C as compared to
the wild-type receptor. In contrast to the above ex-
planation, it is possible that the Western blot and
binding analyses provide a semi-quantitative assess-
ment of the number of S259P receptor molecules in
these cells. If this is correct, it appears that only a
very small number of S259P receptor molecules are
required for induction of the mating pathway. Fur-
thermore, this may indicate that triggering of only a
small fraction of the wild-type receptors is necessary
for signal transduction.
A number of single-site mutations of TM6 of
Ste2p have been identi¢ed including P258L [15],
S254F [15], and L255S [16]. In addition, the muta-
tion Y266C in TM6 suppresses the E143K mutation
in TM3 indicating a speci¢c interaction between
TM3 and TM5 involving residues 266 and 143 [13].
These studies and our results with receptor S259P
support the hypothesis that TM6 is important for
the conformational switch of Ste2p from an inactive
to an active state.
Ligand speci¢c conformational changes of the
K-factor receptor have been recently investigated us-
ing limited trypsin digestion of the receptor in the
presence of agonist and antagonist peptides [25]. In
the native receptor, the K-factor peptide seems to
promote a distinct conformational state that favors
interaction of the third cytoplasmic loop with the
G-protein [17,19] while an antagonist peptide pro-
motes a di¡erent conformation than the signal-induc-
ing isomerization state. The F55V, S219P, and S259P
mutant receptors may contain mutations that a¡ect
the isomerization state allowing for a receptor con-
formation energetically shifted towards the active
conformation and creating a receptor wherein an
antagonist peptide is capable of inducing the propa-
gation of the mating signal. Clearly, we need to map
the binding domain of Ste2p in order to understand
how the pheromone^receptor interaction leads to in-
itiation of signal transduction. Biochemical and bio-
physical characterization of mutant receptors and
properly designed pheromone analogs will generate
information that should lead to a better understand-
ing of this GPCR.
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